Neoadjuvant PD-L1 blockade was well tolerated with a lower incidence of treatment-related adverse events compared with standard-of-care chemotherapy/chemoradiotherapy in resectable ESCC, consistent with observations in lung cancer7,29 and advanced esophageal cancer12,30–34. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.